| [1] | TALLMAN M S, NABHAN C, FEUSNER J H, et al. Acute promyelocytic leukemia: evolving therapeutic strategies[J]. Blood, 2002, 99(3): 759-767. doi: 10.1182/blood.V99.3.759 |
| [2] | PLATZBECKER U, AVVISATI G, CICCONI L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial[J]. J Clin Oncol, 2017, 35(6): 605-612. doi: 10.1200/JCO.2016.67.1982 |
| [3] | KUMANA C R, MAK R, KWONG Y L, et al. Resurrection of oral arsenic trioxide for treating acute promyelocytic leukaemia: a historical account from bedside to bench to bedside[J]. Front Oncol, 2020, 10: 1294. doi: 10.3389/fonc.2020.01294 |
| [4] | AU W Y, KUMANA C R, KOU M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia[J]. Blood, 2003, 102(1): 407-408. doi: 10.1182/blood-2003-01-0298 |
| [5] | GILL H, YIM R, LEE H K K, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: a 15-year prospective study[J]. Cancer, 2018, 124(11): 2316-2326. doi: 10.1002/cncr.31327 |
| [6] | GILL H, AU W Y, KWONG Y L. Oral arsenic trioxide - based maintenance without hematopoietic stem cell transplantation At second remission in acute promyelocytic leukemia - a prospective follow-up study of 65 patients[J]. Blood, 2013, 122(21): 2678. doi: 10.1182/blood.v122.21.2678.2678 |
| [7] | GILL H, KUMANA C R, YIM R, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: a 5-year prospective study[J]. Cancer, 2019, 125(17): 3001-3012. doi: 10.1002/cncr.32180 |
| [8] | GRAD J M, BAHLIS N J, REIS I, et al. Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells[J]. Blood, 2001, 98(3): 805-813. doi: 10.1182/blood.V98.3.805 |
| [9] | TISDALE J E. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management[J]. Can Pharm J, 2016, 149(3): 139-152. doi: 10.1177/1715163516641136 |
| [10] | MAEDA T, NAJIMA Y, KAMIYAMA Y, et al. Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology[J]. Int J Clin Oncol, 2024, 29(5): 535-544. doi: 10.1007/s10147-023-02465-0 |
| [11] | National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 2.2026 [EB/OL]. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1415 [Z]. |
| [12] | 中华医学会血液学分会, 中国医师协会血液科医师分会. 中国急性早幼粒细胞白血病诊疗指南(2018年版) [J]. 中华血液学杂志. 2018, 39(3): 179-183. |
| [13] | Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell R. The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med[J]. 1992;117: 292. |
| [14] | Shuang Han, Yiqun Zhao, et al. Advances in differentiation syndrome in acute promyelocytic leukemia: From mechanisms to management. Blood reviews[J]. 2026 Aug 26;: 101419. |
| [15] | GILL H S, YIM R, KUMANA C R, et al. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators[J]. Cancer, 2020, 126(14): 3244-3254. doi: 10.1002/cncr.32937 |